Since trials investigating the potential use of anti-BRAF agents in the management of gliomas are ongoing, it cannot be excluded, in case of successful results, that the testing of BRAF status in ...

The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

The Phase 2 PHAROS trial is an open-label, multicenter, single arm study examining BRAFTOVI + MEKTOVI combination therapy in treatment-naive and previously treated patients with BRAF V600E-mutant ...

This study focused on patients with RAS/BRAF wild-type (WT) mCRC who were not previously treated with anti-epidermal growth factor receptor (EGFR) therapy. RYBREVANT is a fully-human bispecific ...

Mr. Yusheng Han, Founder and CEO of Burning Rock stated: "We are thrilled to have carried out a deep companion diagnostic collaboration with the global biopharmaceutical company Dizal. This ...

demonstrated promising rapid and durable antitumour activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer or mCRC who have not previously received anti-epidermal growth ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

This oral presentation will include patient demographics, safety, pharmacokinetic, pharmacodynamic and anti-tumor activity ... a Novel BiDAC™ Degrader in Mutant BRAF V600 Solid Tumors ...